Lorundrostat Hits 46% SBP Control in Resistant Hypertension, Expands OSA Data
MLYS is trading near its 52-week low of $21.46 (4.1% above the low) on elevated volume (2.1× avg).
Summary
Mineralys reported detailed Phase 3 Launch-HTN data showing 46% of patients on lorundrostat 50 mg achieved systolic blood pressure below 130 mmHg at 12 weeks, with 70% seeing at least a 10 mmHg reduction. Phase 2 Explore-OSA showed an 11.1 mmHg morning SBP drop versus 1.0 mmHg on placebo, though no measurable change in AHI. This adds granular efficacy numbers to the pivotal data first reported in August, reinforcing the drug's profile in difficult-to-treat hypertension and supporting the December 2026 FDA decision. Safety remains clean with no hyperkalemia signal, a key differentiator for aldosterone synthase inhibitors. The stock trades near its 52-week low, so positive late-stage data could drive a re-rating ahead of the PDUFA date.
At the time of this announcement, MLYS was trading at $22.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $21.46 to $47.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.